A small trial suggests the drug liraglutide bolsters glucose metabolism in the brains of people with Alzheimer’s, but whether this modifies their disease remains unknown.
Researchers find high levels of certain pesticides in the blood of people with ALS, while in neuronal cultures some of them caused gene expression changes reminiscent of Alzheimer’s.
Nuances in episodic memory can tell if primary progressive aphasia is due to non-tangle types of tau pathology or to plaques and tangles.
Scientists match up PET scans of neurofibrillary tangles against Aβ imaging, CSF measures, and cognitive tests to see how biomarkers change relative to function.
Researchers have tied sleep to clearance of waste products such as excess Aβ. New research suggests this clearance may be driven by a change in the extracellular ion composition, which swells the interstitial fluid. Other work finds an essential role for ...
Researchers find essential roles for a signaling pathway involving the kinase complex mTORC1 and the electrical rhythms of REM sleep.
Changing the mix of extracellular ions can put neurons to sleep and swell the brain interstitial fluid for better solute flow.
Knocking down TIA1 rescues tau pathology and toxicity in cells.
PKCα helps Aβ weaken synapses, and rare mutations in some Alzheimer’s families make the enzyme more active.
Zilkha conference features news on tau toxicity, a leaky blood-brain barrier, and the biology of pericytes.
After years of doubt, leading scientists are growing cautiously excited about the idea that bacteria might seed plaques.
Aβ Oligomers Purified from Human Brain Microbial Hypotheses Intrigue at Zilkha Alzheimer’s Meeting What’s Up With the Vasculature in Dementia? At the third annual Zilkha Symposium, held April 15, 2016, in Los Angeles, scientists from the United States and ...
A comparison of blood proteins between health and dementia uncovers faulty differentiation signaling, which may have harmful effects on neurogenesis.
The gene-editing technology helps validate risk factors of disease and build better disease models.
Search begins for director of £250 million venture.